Eyam Vaccines Secures Grant to Advance Gemini Expression Platform
Summary
Vancouver, BC / ACCESSWIRE / September 10, 2024 / Eyam Vaccines and Immunotherapeutics has announced a new grant from the Bill & Melinda Gates Foundation. Eyams CEO, Ryan M. Thomas, stated that this grant is a significant step for the Gemini platform, potentially unlocking new opportunities in developing long-lasting, cost-effective treatments for various diseases.Dr. Terry Pearson, member of Eyams Board of Directors, highlighted the platforms potential to improve monoclonal antibody therapies. The technology could enhance treatment effectiveness and reduce the need for frequent dosing, thus improving patient compliance.The Gemini Platform offers the possibility of sustained therapeutic effects with minimal dosing, potentially transforming the delivery of protein-based therapies. Dr. Wilfred Jefferies, Chief Scientific Officer, emphasized that the Gemini Platform represents a significant advancement in therapeutic delivery.The proof-of-concept study will commence immediately, focusing on preclinical evaluations to validate the platforms long-term protein expression capabilities.